Lys372

Site Information
EEPLPtkkWPtVDAs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 15384501

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 )
Disease tissue studied:	leukemia ( 4 ) , chronic myelogenous leukemia ( 4 )
Relevant cell line - cell type - tissue:	HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , K562 (erythroid) ( 4 ) , U2OS (bone cell) ( 3 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98 23000965 Curated Info
4	Guo A (2010) CST Curation Set: 9185; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info